The nightly ledger

Stock catalysts from the latest SEC filings

Every 8-K, 10-Q and 10-K that AIR's companies filed on SEC EDGAR, and what each one changed in AIR's read. Material filings first, newest first — never ordered by price. For 8-K filing alerts, follow a company and turn on filing emails.

By event type: Acquisitions · Major contracts

Seven-day window, 1 week back · Material filings: 447 · All filings: 661

Material

Thursday 12 Nov175 filings read · 119 material

  • 8-KFiled 12 Nov 2026All industries

    ARKO Corp.ARKO

    8-K · Item 2.01 — Acquisition or disposal of assets

    ARKO completed acquisition of U.S. Petroleum Partners' fuel supply and distribution business in Great Lakes region for ~$200M cash plus $30M in stock. Adds two terminals, ~400 dealer locations, and fleet operations.

    Value: Strong 72 → Watch 43Gap Very high · 92 → Very high · 98

    The shares became dearer on AIR's value read.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026All industries

    Lithium Americas Corp.LAC

    8-K · Item 2.02 — Results of operations

    Lithium Americas raised Thacker Pass Phase 1 capex estimate from $2.93B to $3.83B (+31%), driven by labor inflation ($395M), tariffs/logistics ($100M), EPCM costs ($250M), and contingency increases. Requires ~$995M additional funding.

    No notable change in AIR's read.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Vor Biopharma Inc.VOR

    8-K · Items 1.01, 3.02 — Material agreement

    Vor Biopharma expanded its RemeGen license agreement to include RC298, a next-generation dual BAFF/APRIL inhibitor. The company receives exclusive rights outside Greater China in exchange for $10M upfront, 2.3M pre-funded warrants, and up to $300M in development milestones.

    News flow: Balanced 54 → Balanced 58Gap Very high · 71 → Very high · 93

    The filings read more positively.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Assembly Biosciences, Inc.ASMB

    8-K · Item 2.02 — Results of operations

    Assembly Bio initiated Phase 2 study of ABI-6250 in chronic hepatitis delta virus, exercised 40% U.S. profit-share option for HSV program with Gilead, and received $75M collaboration extension fee, extending cash runway to 2029.

    Gap High · 29 → High · 39

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Anaptysbio, IncANAB

    8-K · Item 2.02 — Results of operations

    AnaptysBio reported Q1 FY2027 results with Jemperli achieving $1.0B in nine-month sales (29% YoY growth) and FDA approval in rectal cancer. Litigation with GSK/Tesaro post-trial hearing held; judgment expected Q4 2026/Q1 2027. Quimilza FDA decision due December 2026.

    Gap High · 28 → High · 39

    Progress is running ahead of attention.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 12 Nov 2026Semiconductors

    Diodes Inc /Del/DIOD

    8-K · Item 2.02 — Results of operations

    Diodes reported Q3 2026 record revenue of $532.6M (+36% YoY, +20% QoQ) with gross margin expanding 510 bps to 36.1%. Q4 guidance projects $550M revenue (+40% YoY) and 37% gross margin. Strong demand across automotive, industrial, and AI applications.

    No notable change in AIR's read.

    More facts
    Momentum: Watch
    Material
  • 10-QFiled 12 Nov 2026Industrials

    EnerSysENS

    Quarterly report (10-Q), period ending 4 Oct 2026

    Value: Balanced 55 → Balanced 58Gap Medium · 23 → High · 41

    The shares became cheaper on AIR's value read.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 10-QFiled 12 Nov 2026All industries

    MIDDLEBY CorpMIDD

    Quarterly report (10-Q), period ending 3 Oct 2026

    Value: Watch 26 → Weak 22Gap Very high · 58 → Very high · 55

    The shares became dearer on AIR's value read.

    The gap narrowed — attention is catching up.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 12 Nov 2026All industries

    Akamai Technologies IncAKAM

    8-K · Items 1.01, 2.03, 3.02 — Material agreement

    Akamai completed a $2.5B convertible note offering ($1.25B due 2028 at 1.00%, $1.25B due 2031 at 1.00%). Proceeds will refinance 2027 notes, fund Cloud Infrastructure Services capex, and support general corporate purposes. Management expects EBITDA margin and cash flow improvement from 2027 onward.

    News flow: Balanced 55 → Balanced 52Gap Very high · 59 → Medium · 22

    The filings read less positively.

    The gap narrowed as the filings read less positively.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 10-QFiled 12 Nov 2026Biotech

    Relmada Therapeutics, Inc.RLMD

    Quarterly report (10-Q), period ending 30 Sep 2026

    Gap Medium · 17 → High · 31

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Relmada Therapeutics, Inc.RLMD

    8-K · Item 2.02 — Results of operations

    Relmada reports 18-month Phase 2 durability data for NDV-01 showing 86% complete response maintenance with no Grade ≥3 adverse events. IND submission on track for year-end 2026; Phase 3 SPECTRUM program renamed; $202.1M cash runway through 2029.

    Gap Medium · 17 → High · 31

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Prime Medicine, Inc.PRME

    8-K · Item 2.02 — Results of operations

    Prime Medicine dosed first patient in Phase 1/2 trial of PM577a (Wilson disease), received FDA IND clearance for PM647 (Alpha-1 Antitrypsin Deficiency), and raised $143.7M gross proceeds. BLA submission planned for PM359 in H1 2027. Cash runway extended through 2027.

    Recognition: Balanced 64 → Strong 68Gap Low · 3 → High · 29

    More of the market is starting to notice.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 12 Nov 2026Biotech

    CorMedix Inc.CRMD

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue of $54.5M beat consensus ($51.2M). Announced definitive agreement to acquire Heron Therapeutics assets (expected $125–150M annual revenue contribution in 2027, immediately accretive). FDA granted Priority Review for REZZAYO sNDA (PDUFA Q1 2027). Secured $150M term loan facility.

    News flow: Balanced 52 → Balanced 56Recognition: Balanced 46 → Watch 43Gap Very high · 48 → Very high · 87

    The filings read more positively.

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 10-QFiled 12 Nov 2026Biotech

    CorMedix Inc.CRMD

    Quarterly report (10-Q), period ending 30 Sep 2026

    News flow: Balanced 52 → Balanced 56Recognition: Balanced 46 → Watch 43Gap Very high · 48 → Very high · 87

    The filings read more positively.

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Kyverna Therapeutics, Inc.KYTX

    8-K · Item 2.02 — Results of operations

    Kyverna completed BLA submission for miv-cel in stiff person syndrome with priority review request. One-year data showed durable efficacy, disability reversal, and consistent safety. KYSA-6 gMG trial enrollment on-track for mid-2027 completion. Cash runway extends into 2028.

    Gap Very high · 59 → Very high · 68

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026Industrials

    Spectrum Brands Holdings, Inc.SPB

    8-K · Item 2.02 — Results of operations

    SPB reported FY2026 results with mixed signals: full-year adjusted EBITDA of $374.8M ahead of consensus (excluding $57.4M tariff refunds), but Q4 net sales declined 2.8% organically. FY2027 guidance is flat to low single-digit growth. Strategic Helen of Troy acquisition proposal rejected.

    Recognition: Strong 65 → Balanced 62Value: Weak 16 → Weak 24Gap Medium · 11 → Medium · 18

    Market attention has faded.

    The shares became cheaper on AIR's value read.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Balanced
    Material
  • 10-QFiled 12 Nov 2026Biotech

    Immix Biopharma, Inc.IMMX

    Quarterly report (10-Q), period ending 30 Sep 2026

    Recognition: Watch 42 → Watch 39Gap High · 33 → Very high · 45

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Alkermes plc.ALKS

    8-K · Item 1.01 — Material agreement

    Alkermes settled patent infringement lawsuit with Teva, granting a royalty-free license to market generic LYBALVI beginning November 2039 (or May 2040 with pediatric exclusivity). Settlement resolves ANDA challenge and provides market exclusivity extension.

    Gap Very high · 53 → Very high · 65

    Progress is running ahead of attention.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 12 Nov 2026All industries

    Host Hotels & Resorts, Inc.HST

    8-K · Items 1.01, 8.01 — Material agreement

    HST entered into a new $600M at-the-market distribution agreement with 11 financial institutions, replacing its prior May 2023 agreement. The program allows opportunistic share sales at market prices for acquisitions and general corporate purposes.

    No notable change in AIR's read.

    More facts
    Momentum: Very strong
    Material
  • 8-KFiled 12 Nov 2026All industries

    Natural Gas Services Group IncNGS

    8-K · Item 2.02 — Results of operations

    NGS reported Q3 2026 results with record rental revenue and adjusted EBITDA. Company raised full-year guidance, increased dividend 60%, completed Flatrock integration successfully, and achieved 43,000 HP organic growth on track for 55,000 HP annual target.

    Gap Very high · 77 → Very high · 90

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 10-QFiled 12 Nov 2026All industries

    Aebi Schmidt Holding AGAEBI

    Quarterly report (10-Q), period ending 30 Sep 2026

    Recognition: Watch 30 → Watch 25Gap High · 25 → Medium · 10

    Market attention has faded.

    The gap narrowed as the filings read less positively.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026All industries

    Installed Building Products, Inc.IBP

    8-K · Items 1.01, 3.02 — Material agreement

    IBP completed acquisition of Old Dominion Group for $698M enterprise value, adding $370M LTM revenue and $68M EBITDA. Expands commercial end-market exposure from ~20% to ~28%, expected immediately accretive to revenue, margins, and EPS with $6-8M run-rate synergies.

    News flow: Balanced 49 → Balanced 54Recognition: Watch 38 → Watch 43Gap Low · 0 → Very high · 72

    The filings read more positively.

    More of the market is starting to notice.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 12 Nov 2026Industrials

    EnerSysENS

    8-K · Items 2.02, 8.01 — Results of operations

    EnerSys reported Q2 FY2027 results with flat sales ($950M) but gross margin expansion to 29.9% (+80 bps), adjusted EPS of $3.22 (+22%), and announced definitive agreement to acquire Ultralife to expand defense power platform.

    Value: Balanced 55 → Balanced 58Gap Medium · 23 → High · 41

    The shares became cheaper on AIR's value read.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Kardigan, Inc.KARD

    8-K · Item 2.02 — Results of operations

    Kardigan completed Phase 2b enrollment in danicamtiv KINSHIP-DCM trial with topline data expected Q2 2027; completed ataciguat KATALYST-AV Phase 2b enrollment with Week 48 data expected H2 2027. Cash position of $591.4M supports multiple data readouts and Phase 3 initiation through 2027.

    Gap Low · 0 → Medium · 21

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Candel Therapeutics, Inc.CADL

    8-K · Item 2.02 — Results of operations

    Candel reported Q3 2026 results with positive clinical data for aglatimagene across prostate cancer, NSCLC, and linoserpaturev in glioma. BLA submission planned mid-2027. Cash position of $203.1M funds operations into Q2 2028. Key hires strengthen commercial readiness.

    Recognition: Watch 43 → Watch 36Value: Balanced 57 → Watch 36Gap High · 42 → Very high · 56

    Market attention has faded.

    The shares became dearer on AIR's value read.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 12 Nov 2026All industries

    Aebi Schmidt Holding AGAEBI

    8-K · Item 2.02 — Results of operations

    Q3 2026 showed revenue growth of 4.6% and net income improvement, but full-year guidance was reduced. Adjusted EBITDA guidance lowered from $175–195m to $170–180m; net sales guidance narrowed from $1.95–2.15b to $1.95–2.00b. Gross margin pressured by inflation; leverage guidance relaxed to <2.5x from 2.0x.

    Recognition: Watch 30 → Watch 25Gap High · 25 → Medium · 10

    Market attention has faded.

    The gap narrowed as the filings read less positively.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026Banks

    Jefferson Capital, Inc. / DEJCAP

    8-K · Item 2.02 — Results of operations

    Jefferson Capital reported Q3 2026 results with record collections (+35% YoY to $319.2M), record deployments (+111% to $318.0M), record ERC (+23% to $3.6B), and record revenue (+23% to $185.5M). Net income of $46.9M and EPS of $0.76 delivered.

    Gap Very high · 56 → Very high · 64

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Erasca, Inc.ERAS

    8-K · Item 2.02 — Results of operations

    Erasca announced FDA Fast Track Designation for ERAS-0015 in metastatic pancreatic cancer, strengthened cash position to $948M via upsized financing, appointed experienced R&D leadership, and advanced toward three registration-enabling trials in pancreatic and lung cancers.

    Gap Medium · 15 → Medium · 22

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Greenland Mines LtdGRML

    8-K · Items 1.01, 3.02, 8.01 — Material agreement

    GRML entered a subscription agreement to purchase 7M BMR shares (C$1.4M) and exercised an option to acquire 25.2M AnorTech shares (C$7.6M), paying via 1.1M newly issued GRML shares. Both transactions are subject to regulatory approval.

    Recognition: Watch 29 → Watch 38Gap Very high · 98 → Very high · 95

    The gap narrowed — attention is catching up.

    More facts
    Momentum: Weak
    Material
  • 10-QFiled 12 Nov 2026Banks

    Jefferson Capital, Inc. / DEJCAP

    Quarterly report (10-Q), period ending 30 Sep 2026

    Gap Very high · 56 → Very high · 64

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 10-QFiled 12 Nov 2026All industries

    Fermi Inc.FRMI

    Quarterly report (10-Q), period ending 30 Sep 2026

    Gap Very high · 85 → Very high · 88

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 10-QFiled 12 Nov 2026Industrials

    NeuroPace IncNPCE

    Quarterly report (10-Q), period ending 30 Sep 2026

    Gap Low · 6 → Low · 0

    Attention caught up with the documented progress.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 10-QFiled 12 Nov 2026All industries

    TMC the metals Co Inc.TMC

    Quarterly report (10-Q), period ending 30 Sep 2026

    Gap Very high · 53 → Very high · 61

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026Biotech

    SELLAS Life Sciences Group, Inc.SLS

    8-K · Item 2.02 — Results of operations

    SELLAS announced Q3 2026 results with $134.7M cash, Phase 3 REGAL trial 80th event triggering topline results expected this month, Phase 2 SLS009 enrollment at 40/80 patients with Q4 data expected, and favorable Phase 2 relapsed/refractory AML data (54-57% ORR).

    Recognition: Watch 39 → Watch 32Gap High · 28 → Very high · 45

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Monopar TherapeuticsMNPR

    8-K · Item 2.02 — Results of operations

    Monopar presented Phase 3 baseline data for ALXN1840 in Wilson disease showing significant disease burden in treatment-experienced patients. Company initiated rolling NDA submission to FDA and hired experienced medical affairs executive. Cash position of $129.4M supports operations through March 2028.

    Gap Low · 3 → Medium · 16

    Progress is running ahead of attention.

    More facts
    Momentum: Watch
    Material
  • 10-QFiled 12 Nov 2026Software / SaaS

    NIQ Global Intelligence plcNIQ

    Quarterly report (10-Q), period ending 30 Sep 2026

    Recognition: Balanced 60 → Balanced 57Gap Low · 0 → Medium · 22

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Very strong
    Material
  • 8-KFiled 12 Nov 2026All industries

    Enterprise Products Partners L.P.EPD

    8-K · Items 1.01, 8.01 — Material agreement

    EPD completed a $1.5 billion senior notes offering ($750M due 2032 at 5.20%, $750M due 2037 at 5.65%). Proceeds will fund growth investments, acquisitions, and debt repayment of maturing notes.

    No notable change in AIR's read.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Twist Bioscience CorpTWST

    8-K · Item 2.02 — Results of operations

    Twist Bioscience reported FY2026 record revenue of $459.4M (+22% YoY), gross margin expansion to 52.4%, and positive adjusted EBITDA in Q4. FY2027 guidance of $550–560M revenue (+21% midpoint) with expected positive adjusted EBITDA.

    Recognition: Strong 79 → Strong 76Value: Watch 37 → Watch 43Gap Medium · 19 → High · 27

    Market attention has faded.

    The shares became cheaper on AIR's value read.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 12 Nov 2026All industries

    Aveanna Healthcare Holdings, Inc.AVAH

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue grew 11.8% YoY to $695.5M; net income surged to $45.5M from $14.1M; Adjusted EBITDA increased 25.0% to $100.1M. Full-year 2026 revenue and Adjusted EBITDA guidance raised.

    Recognition: Balanced 57 → Balanced 54Value: Weak 16 → Weak 20Gap Medium · 18 → High · 30

    Market attention has faded.

    The shares became cheaper on AIR's value read.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 12 Nov 2026Industrials

    YETI Holdings, Inc.YETI

    8-K · Item 2.02 — Results of operations

    YETI reported Q3 2026 adjusted sales growth of 6% and adjusted EPS growth of 49%, but reduced full-year 2026 outlook. Adjusted sales growth guidance lowered from 7-8% to ~6%; adjusted EPS guidance narrowed from $2.94-$3.00 to $2.90-$2.95. Management cited cautious consumer environment and uneven demand.

    Recognition: Balanced 52 → Balanced 45Value: Balanced 55 → Strong 69Gap Low · 4 → Low · 0

    Market attention has faded.

    The shares became cheaper on AIR's value read.

    The gap closed as the filings read less positively.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 10-QFiled 12 Nov 2026Industrials

    Heartflow, Inc.HTFL

    Quarterly report (10-Q), period ending 30 Sep 2026

    Recognition: Strong 72 → Strong 68Gap Low · 5 → Medium · 13

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Strong
    Material

Tuesday 10 Nov146 filings read · 93 material

  • 8-KFiled 10 Nov 2026Industrials

    Janus International Group, Inc.JBI

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue declined 2.8% YoY to $213.1M; net loss of $13.3M vs. prior-year profit; Adjusted EBITDA fell 22% to $34M. Full-year 2026 guidance reduced significantly, with Adjusted EBITDA now $127–133M (down 22.7% at midpoint). Goodwill impairment of $18.3M recorded.

    No notable change in AIR's read.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 10 Nov 2026All industries

    Advanced Drainage Systems, Inc.WMS

    8-K · Item 1.01 — Material agreement

    Advanced Drainage Systems increased revolving credit commitments by $300M to $1.05B total and added supply chain and receivables financing capabilities, enhancing liquidity and operational flexibility.

    Gap Very high · 72 → Very high · 84

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 10 Nov 2026Software / SaaS

    D-Wave Quantum Inc.QBTS

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue up 21% YoY to $4.5M; YTD bookings surged 611% to $37.4M. RPO jumped 1,221% to $38.3M. Secured $100M CHIPS Act funding. Announced major partnerships with NTT DOCOMO, CGI, LG CNS; deployed systems in Italy.

    Gap High · 31 → High · 40

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 10-QFiled 10 Nov 2026Industrials

    Mercury Systems IncMRCY

    Quarterly report (10-Q), period ending 2 Oct 2026

    Value: Watch 25 → Weak 20Gap Low · 0 → High · 36

    The shares became dearer on AIR's value read.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 10 Nov 2026Biotech

    Liquidia CorpLQDA

    8-K · Items 2.02, 8.01 — Results of operations

    YUTREPIA Q3 2026 net sales reached $222.7M (31% QoQ growth). Company resolved all litigation with United Therapeutics via $380.7M settlement, securing uninterrupted patient access. Fifth consecutive quarter of positive adjusted EBITDA ($140.5M). Fast Track designation granted for SSc-RP indication.

    No notable change in AIR's read.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 10 Nov 2026Industrials

    Mercury Systems IncMRCY

    8-K · Items 2.02, 5.02 — Results of operations

    Mercury Systems reported record Q1 FY27 bookings ($370M, +48% YoY), revenue ($253M, +12.4% YoY), adjusted EBITDA ($56M, +58.6% YoY), and backlog ($2.1B, +44.7% YoY). Company raised FY27 outlook based on solid execution.

    Value: Watch 25 → Weak 20Gap Low · 0 → High · 36

    The shares became dearer on AIR's value read.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 10 Nov 2026Biotech

    Veradermics, IncMANE

    8-K · Item 2.02 — Results of operations

    Veradermics reported positive Phase 3 and Phase 2/3 trial results for VDPHL01 in male and female pattern hair loss, with robust hair growth, favorable safety profiles, and strong cash position of $798.4M funding operations into 2030.

    Gap High · 42 → Very high · 57

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Very strong
    Material
  • 8-KFiled 10 Nov 2026All industries

    Anterix Inc.ATEX

    8-K · Item 2.02 — Results of operations

    Anterix reported Q2 FY2027 net loss of $4.993M vs. prior-year net income of $53.536M. Spectrum revenue grew modestly to $1.958M, but operating losses and negative cash flow from operations signal execution challenges despite $107.5M cash balance and spectrum licensing progress.

    Gap Low · 4 → Low · 0

    The gap closed as the filings read less positively.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 10 Nov 2026All industries

    Sixth Street Specialty Lending, Inc.TSLX

    8-K · Item 1.01 — Material agreement

    TSLX established a $100M at-the-market equity distribution program with five sales agents. The company may issue common stock at or above NAV, with proceeds for general corporate purposes and debt repayment. No shares have been sold yet.

    No notable change in AIR's read.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 10 Nov 2026Biotech

    Tyra Biosciences, Inc.TYRA

    8-K · Item 2.02 — Results of operations

    Tyra reported Phase 2 SURF302 results showing 79% ORR and 64% CR rate for dabogratinib in IR NMIBC, completed $400M financing providing runway through 2030, and advanced three Phase 2 programs across oncology and rare disease indications.

    Gap Medium · 14 → High · 28

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 10 Nov 2026Biotech

    Alto Neuroscience, Inc.ANRO

    8-K · Item 2.02 — Results of operations

    Alto Neuroscience reported Q3 2026 results with $319.8M cash position (up from $177M), enabling operations through 2030. PACE-1 trial on track for 2H 2027 data; Phase 3 expansion approved. $100M financing completed in July 2026.

    Recognition: Balanced 53 → Balanced 57

    More of the market is starting to notice.

    The price trend strengthened.

    More facts
    Momentum: Strong
    Material
  • 10-KFiled 10 Nov 2026All industries

    BrightView Holdings, Inc.BV

    Annual report (10-K), FY2026

    Fundamentals: Watch 31 → Watch 27Value: Balanced 52 → Balanced 55Gap Very high · 59 → Very high · 48

    The reported numbers weakened.

    The shares became cheaper on AIR's value read.

    The gap narrowed as the filings read less positively.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 10-QFiled 10 Nov 2026All industries

    Dakota Gold Corp.DC

    Quarterly report (10-Q), period ending 30 Sep 2026

    Recognition: Balanced 52 → Balanced 47

    Market attention has faded.

    The price trend weakened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 10 Nov 2026Biotech

    Achieve Life Sciences, Inc.ACHV

    8-K · Item 2.02 — Results of operations

    AchieveRx reported positive 52-week ORCA-OL trial data showing quit rates rising to 31.2% by end of treatment in hard-to-treat smokers. NDA resubmission on track for Q4 2026 with potential FDA approval by Q2 2027. Strong cash position of $201.5M supports launch readiness.

    Gap Low · 0 → Medium · 14

    Progress is running ahead of attention.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 10 Nov 2026Industrials

    Hyliion Holdings Corp.HYLN

    8-K · Item 2.02 — Results of operations

    Hyliion reported Q3 2026 revenue of $7.5M (vs. $0.8M prior year), raised full-year guidance to ~$18M from $15M, and announced ~$50M in total new military awards for 2026. Delivered KARNO units to Navy and first commercial customer; $45.5M in remaining authorized military contract funding provides revenue visibility.

    Recognition: Watch 36 → Watch 28Gap Low · 1 → Medium · 19

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 10 Nov 2026Biotech

    Capricor Therapeutics, Inc.CAPR

    8-K · Item 2.02 — Results of operations

    Capricor announced Q3 2026 results with Deramiocel BLA under FDA review (PDUFA Nov 22). Two-year HOPE-3 open-label extension data showed 76% slowing of upper limb decline; cardiac results won AHA award. Cash position $198.5M; manufacturing facility operational.

    Gap High · 25 → High · 36

    Progress is running ahead of attention.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 10 Nov 2026Banks

    Forward Industries, Inc.FWDI

    8-K · Item 1.01 — Material agreement

    Forward Industries increased SOL holdings by 226,396 SOL (2.7%) to 8.7M SOL, raising SOL per share 2.3% in 40 days. Secured $50M credit facility, committed $50M to USHP tokenized housing index, and added Barclays as ATM sales agent.

    Recognition: Balanced 56 → Balanced 53Gap Low · 0 → Low · 5

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 10-KFiled 10 Nov 2026Semiconductors

    Skyworks Solutions, Inc.SWKS

    Annual report (10-K), FY2026

    Fundamentals: Balanced 55 → Balanced 46Recognition: Very strong 88 → Very strong 92Gap High · 25 → Medium · 17

    The reported numbers weakened.

    The gap narrowed — attention is catching up.

    The price trend strengthened.

    More facts
    Momentum: Very strong
    Material
  • 10-QFiled 10 Nov 2026Biotech

    Arbutus Biopharma CorpABUS

    Quarterly report (10-Q), period ending 30 Sep 2026

    Gap High · 44 → Very high · 48

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 10 Nov 2026Semiconductors

    Kopin CorpKOPN

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue grew 52% YoY to $18.2M; operating loss narrowed to $0.5M sequentially. Additional $18.6M U.S. Army IBAS award (total $34M) and Neural I/O on track for CES 2027 demonstration. New $2.4M OLED order received.

    Gap Very high · 73 → Very high · 78

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 10 Nov 2026Industrials

    Amprius Technologies, Inc.AMPX

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue of $39.1M (+83% YoY), net loss improved to $3.5M. Company raised 2026 revenue outlook to $145M and secured $75M U.S. Department of War contract for NDAA-compliant cell production.

    No notable change in AIR's read.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 10 Nov 2026Biotech

    Gossamer Bio, Inc.GOSS

    8-K · Item 2.02 — Results of operations

    Gossamer submitted first NDA for seralutinib in PAH to FDA in September 2026. Secured $25M upfront with up to $125M additional capital upon FDA acceptance. Reacquired worldwide rights from Chiesi. Cash position $51.2M as of Q3 2026.

    Recognition: Weak 24 → Watch 38Gap Medium · 11 → Medium · 21

    More of the market is starting to notice.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 10 Nov 2026All industries

    Alliance Laundry Holdings Inc.ALH

    8-K · Item 2.02 — Results of operations

    Q3 2026 net revenues $461M (+5% YoY), net income $65M, Adjusted EBITDA $127M (+14% YoY, 27.5% margin). Full-year Adjusted EBITDA guidance raised to ~10% growth (high end of prior 8-10% range). Net Leverage improved to 2.25x; $45M debt repaid, $75M stock repurchased.

    Gap High · 28 → High · 42

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 10-QFiled 10 Nov 2026All industries

    Alliance Laundry Holdings Inc.ALH

    Quarterly report (10-Q), period ending 30 Sep 2026

    Gap High · 28 → High · 42

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 10-QFiled 10 Nov 2026Industrials

    Hyliion Holdings Corp.HYLN

    Quarterly report (10-Q), period ending 30 Sep 2026

    Recognition: Watch 36 → Watch 28Gap Low · 1 → Medium · 19

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 10-QFiled 10 Nov 2026All industries

    Angel Studios, Inc.ANGX

    Quarterly report (10-Q), period ending 30 Sep 2026

    Recognition: Balanced 49 → Balanced 53Gap High · 40 → Very high · 47

    More of the market is starting to notice.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 10-QFiled 10 Nov 2026Biotech

    Scholar Rock Holding CorpSRRK

    Quarterly report (10-Q), period ending 30 Sep 2026

    News flow: Balanced 50 → Balanced 53Gap Low · 9 → Very high · 57

    The filings read more positively.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 10-QFiled 10 Nov 2026All industries

    Resideo Technologies, Inc.REZI

    Quarterly report (10-Q), period ending 3 Oct 2026

    Recognition: Balanced 48 → Balanced 54Value: Balanced 60 → Balanced 45Gap Very high · 84 → Very high · 78

    The shares became dearer on AIR's value read.

    The gap narrowed — attention is catching up.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 10-QFiled 10 Nov 2026Industrials

    Revvity, Inc.RVTY

    Quarterly report (10-Q), period ending 4 Oct 2026

    No notable change in AIR's read.

    More facts
    Momentum: Very strong
    Material
  • 10-QFiled 10 Nov 2026Biotech

    Alto Neuroscience, Inc.ANRO

    Quarterly report (10-Q), period ending 30 Sep 2026

    Recognition: Balanced 53 → Balanced 57

    More of the market is starting to notice.

    The price trend strengthened.

    More facts
    Momentum: Strong
    Material
  • 10-QFiled 10 Nov 2026Semiconductors

    Ambiq Micro, Inc.AMBQ

    Quarterly report (10-Q), period ending 30 Sep 2026

    Recognition: Watch 38 → Watch 33Gap Low · 5 → Medium · 23

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 10-QFiled 10 Nov 2026Software / SaaS

    Rigetti Computing, Inc.RGTI

    Quarterly report (10-Q), period ending 30 Sep 2026

    Gap Very high · 67 → Very high · 71

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 10 Nov 2026Industrials

    Astronics CorpATRO

    8-K · Item 2.02 — Results of operations

    Astronics reported record Q3 2026 sales of $271.7M (+28.5% YoY) and record operating income of $54.0M (19.9% margin). Aerospace segment achieved 23.4% operating margin with record backlog of $670M. Company maintains full-year 2026 guidance of $1.02–$1.04B revenue.

    Value: Watch 36 → Watch 31Gap Medium · 17 → High · 29

    The shares became dearer on AIR's value read.

    Progress is running ahead of attention.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 10 Nov 2026Industrials

    Pacific Biosciences Of California, Inc.PACB

    8-K · Item 1.01 — Material agreement

    PACB entered into a $100M at-the-market equity offering agreement with Allen & Company LLC. The company will sell shares opportunistically at market prices, with Allen receiving up to 3% commission. This dilutes existing shareholders.

    Recognition: Balanced 58 → Balanced 55

    Market attention has faded.

    The price trend weakened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 10 Nov 2026Software / SaaS

    Rigetti Computing, Inc.RGTI

    8-K · Item 2.02 — Results of operations

    Rigetti achieved 99.5% median two-qubit fidelity on 108-qubit system, validating chiplet architecture. Signed $100M definitive agreement with U.S. Department of Commerce under CHIPS Act. Nine-month 2026 revenue grew 110% YoY to $10.9M; full-year guidance ~$20M.

    Gap Very high · 67 → Very high · 71

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 10 Nov 2026Biotech

    Kura Oncology, Inc.KURA

    8-K · Item 2.02 — Results of operations

    KOMZIFTI delivered 53% sequential revenue growth to $13.9M with 30% increase in new patient starts and maintained majority market share. FDA alignment achieved for darlifarnib registrational study. Strong cash position of $492.1M plus $300M financing capacity secured.

    Gap Low · 5 → Medium · 16

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 10 Nov 2026Industrials

    Sonos IncSONO

    8-K · Item 2.02 — Results of operations

    Sonos returned to revenue growth in FY2026 with 7% YoY increase to $1.547B, delivered 39% Adjusted EBITDA growth to $184M, and beat Q4 guidance. Board authorized new $150M share repurchase program.

    Recognition: Balanced 61 → Strong 66Value: Watch 30 → Watch 26Gap Low · 0 → Low · 9

    More of the market is starting to notice.

    The shares became dearer on AIR's value read.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 10 Nov 2026All industries

    Sally Beauty Holdings, Inc.SBH

    8-K · Item 2.02 — Results of operations

    Sally Beauty reported Q4 FY2026 results with 0.6% net sales growth, 22% GAAP diluted EPS growth, and 13% adjusted diluted EPS growth. Full-year adjusted EPS grew 9%. FY2027 guidance provided with comparable sales growth of 1-2% and adjusted operating earnings of $334-347M.

    Gap Low · 3 → Medium · 15

    Progress is running ahead of attention.

    More facts
    Momentum: Strong
    Material
  • 10-QFiled 10 Nov 2026All industries

    Gevo, Inc.GEVO

    Quarterly report (10-Q), period ending 30 Sep 2026

    Recognition: Watch 40 → Balanced 49Value: Balanced 50 → Balanced 53Gap Very high · 49 → Very high · 52

    More of the market is starting to notice.

    The shares became cheaper on AIR's value read.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 10-QFiled 10 Nov 2026All industries

    GLADSTONE LAND CorpLAND

    Quarterly report (10-Q), period ending 30 Sep 2026

    Gap Low · 0 → Medium · 15

    Progress is running ahead of attention.

    More facts
    Momentum: Watch
    Material

Research, not tips. Filings come from SEC EDGAR; AIR's read is recomputed every trading day. A price move is shown as a fact beside a filing, never as the reason it is listed.